Skip to main content

Table 3 Treatment evaluation according to response evaluation criteria in solid tumors (RECIST) version 1.1 and modified (m) RECIST

From: Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma

 

RECIST 1.1

Total (mRECIST)

CR

PR

SD

PD

mRECIST

 CR

4

0

1

0

5

 PR

0

11

8

1

20

 SD

0

0

70

2

72

 PD

0

0

1

77

78

 Non-measurable

0

0

8

8

16

Total (RECIST 1.1)

4

11

88

88

191

  1. CR complete response, PD progressive disease, PR partial response, SD stable disease
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us